Cingöz, Ahmet http://orcid.org/0000-0002-1111-7752
Ozyerli-Goknar, Ezgi
Morova, Tunc
Seker-Polat, Fidan
Esai Selvan, Myvizhi http://orcid.org/0000-0003-4640-5727
Gümüş, Zeynep Hülya http://orcid.org/0000-0002-7364-2202
Bhere, Deepak http://orcid.org/0000-0003-4142-5518
Shah, Khalid http://orcid.org/0000-0002-5474-0974
Solaroglu, Ihsan
Bagci-Onder, Tugba http://orcid.org/0000-0003-3646-2613
Article History
Received: 13 May 2019
Revised: 21 January 2021
Accepted: 4 February 2021
First Online: 25 March 2021
Change Date: 4 March 2024
Change Type: Clarification
Change Details: Editor's note: Readers are alerted that concerns have been raised regarding the reliability of data presented in this article. Further editorial action will be taken if appropriate once the investigation into the concerns is complete and all parties have been given an opportunity to respond in full.
Compliance with ethical standards
:
: KS owns equity in and is a member of the Board of Directors of AMASA Therapeutics, a company developing stem cell-based therapies for cancer. KS’s interests were reviewed and are managed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policies.